Regeneron Pharmaceuticals, Inc. (REGN) Q4 2015 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.29%

Regeneron Pharmaceuticals reported better-than-expected earnings per share, but the stock fell by 6.29% following the announcement. Investors may have reacted negatively due to the lack of revenue details and guidance. The cautious tone from management suggests a focus on long-term growth rather than immediate financial targets.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.83	N/A	+5.01%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, indicating a commitment to pipeline development. However, they did not provide specific guidance for future performance.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.29%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.29%

Key numbers

Management commentary